EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
+17.22%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$2.25B
AUM Growth
+$2.25B
(+25%)
Cap. Flow
+$441M
Cap. Flow
% of AUM
19.64%
Top 10 Holdings %
Top 10 Hldgs %
64.9%
Holding
86
New
20
Increased
10
Reduced
4
Closed
12
Top Buys
| 1 |
Nuvation Bio
NUVB
|
$138M |
| 2 |
AnaptysBio
ANAB
|
$84.7M |
| 3 |
Kura Oncology
KURA
|
$54.3M |
| 4 |
Prothena Corp
PRTA
|
$40.4M |
| 5 |
Edgewise Therapeutics
EWTX
|
$39.8M |
Top Sells
| 1 |
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
|
$40.1M |
| 2 |
Geron
GERN
|
$30.1M |
| 3 |
VINC
Vincerx Pharma, Inc. Common Stock
VINC
|
$10M |
| 4 |
Aclaris Therapeutics
ACRS
|
$9.77M |
| 5 |
CMAX
CareMax, Inc. Class A Common Stock
CMAX
|
$7.51M |
Sector Composition
| 1 | Healthcare | 98.52% |
| 2 | Financials | 0.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Prothena Corp
PRTA
$445M
| $277M | 12.29% |
11,034,280
+1,607,640
| +17% | +$40.4M |
|
2
Xencor
XNCR
$610M
| $211M | 9.36% |
4,900,306
+353,234
| +8% | +$15.2M |
|
|
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $190M | 8.42% |
2,999,315
+159,431
| +6% | +$10.1M |
|
|
4
AnaptysBio
ANAB
$577M
| $154M | 6.84% |
7,151,624
+3,928,300
| +122% | +$84.7M |
|
|
5
Nuvation Bio
NUVB
$1.01B
| $138M | 6.14% |
+13,247,017
| New | +$138M |
|
6
Relay Therapeutics
RLAY
$631M
| $119M | 5.26% |
3,429,363
+228,714
| +7% | +$7.91M |
|
7
ARS Pharmaceuticals
SPRY
$1.1B
| $111M | 4.9% |
2,533,635
| – | – |
|
|
8
Kura Oncology
KURA
$690M
| $104M | 4.63% |
3,692,637
+1,919,600
| +108% | +$54.3M |
|
|
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $79.5M | 3.53% |
464,298
| – | – |
|
10
Oric Pharmaceuticals
ORIC
$1.01B
| $75.8M | 3.36% |
3,092,218
| – | – |
|
11
Shattuck Labs
STTK
$48.4M
| $71.9M | 3.19% |
2,458,259
+1,405
| +0.1% | +$41.1K |
|
12
Nurix Therapeutics
NRIX
$696M
| $62.8M | 2.78% |
2,019,019
+475,000
| +31% | +$14.8M |
|
13
Arcus Biosciences
RCUS
$1.15B
| $61.7M | 2.73% |
2,195,892
| – | – |
|
14
Solid Biosciences
SLDB
$423M
| $50.9M | 2.26% |
9,202,702
+1,225,000
| +15% | +$6.77M |
|
15
Avidity Biosciences
RNA
$6.08B
| $45.9M | 2.04% |
2,103,950
| – | – |
|
|
16
Edgewise Therapeutics
EWTX
$1.57B
| $39.8M | 1.76% |
+1,224,175
| New | +$39.8M |
|
17
Neurogene
NGNE
$280M
| $38.4M | 1.7% |
3,122,704
| – | – |
|
|
BCEL
18
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $37.2M | 1.65% |
2,426,685
| – | – |
|
19
Design Therapeutics
DSGN
$326M
| $34M | 1.51% |
+1,137,940
| New | +$34M |
|
|
GRTS
20
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $32.3M | 1.43% |
3,421,287
| – | – |
|
21
AC Immune
ACIU
$222M
| $27.8M | 1.23% |
3,648,163
+1,237,923
| +51% | +$9.42M |
|
|
AKUS
22
DELISTED
Akouos, Inc. Common Stock
AKUS
| $27.4M | 1.22% |
1,975,984
| – | – |
|
23
Ovid Therapeutics
OVID
$87.5M
| $24.5M | 1.08% |
+6,082,200
| New | +$24.5M |
|
24
Arvinas
ARVN
$580M
| $21.1M | 0.93% |
+318,704
| New | +$21.1M |
|
|
KDNY
25
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $19.4M | 0.86% |
1,250,001
| – | – |
|